**Evidence Table D-6. Intervention characteristics for studies comparing interventions to treat delirium**

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Agar, 2017[17](#_ENREF_17) | 1 | Placebo | Oral | Titrated dose: Maximum 4 mg/d | Twice a day (bid) | Planned duration: 3 days | Orientation and therapeutic activities, Fluid repletion, Vision and hearing | A 0.5 mg loading dose administered with the first dose of 0.5 mg, then 0.5 mg maintenance doses every 12 hours. Doses could be titrated by 0.25 mg on day 1 and by 0.5 mg thereafter to a maximum dose of 4 mg/d; for those patients over the age of 65 the loading, initial and max doses were one half that listed for the remainder of the population. |
|  | 2 | Haloperidol | Oral | Titrated dose: Maximum 4 mg/d | Twice a day (bid) | Planned duration: 3 days | Orientation and therapeutic activities, Fluid repletion, Vision and hearing | A 0.5 mg loading dose administered with the first dose of 0.5 mg, then 0.5 mg maintenance doses every 12 hours. Doses could be titrated by 0.25 mg on day 1 and by 0.5 mg thereafter to a maximum dose of 4 mg/d; for those patients over the age of 65 the loading, initial and max doses were one half that listed for the remainder of the population. |
|  | 3 | Risperidone | Oral | Titrated dose: Maximum 4 mg/d | Twice a day (bid) | Planned duration: 3 days | Orientation and therapeutic activities, Fluid repletion, Vision and hearing | A 0.5 mg loading dose administered with the first dose of 0.5 mg, then 0.5 mg maintenance doses every 12 hours. Doses could be titrated by 0.25 mg on day 1 and by 0.5 mg thereafter to a maximum dose of 4 mg/d; for those patients over the age of 65 the loading, initial and max doses were one half that listed for the remainder of the population. |
| Atalan, 2013[18](#_ENREF_18) | 1 | Haloperidol | Intramuscular | Titrated dose: Maximum 20mg | Per day | Planned duration: Until discharge | Pain management | Postoperative analgesia was achieved by providing 1 g of paracetamol intravenously every 8 hours and 50 mg of dexketoprofen intravenously twice a day. Postoperative pain was recorded once a day using the verbal version of the visual analog scale. |
|  | 2 | morphine sulfate | Intramuscular | Titrated dose: Maximum 20mg | Per day | Planned duration: Until discharge | Pain management | Postoperative analgesia was achieved by providing 1 g of paracetamol intravenously every 8 hours and 50 mg of dexketoprofen intravenously twice a day. Postoperative pain was recorded once a day using the verbal version of the visual analog scale. |

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bakri, 2015[19](#_ENREF_19) | 1 | Dexmedetomidine | Intravenous | Planned dose: 1 ug/kg | Twice a day (bid) | Planned duration: 3 days | None |  |
|  | 2 | Haloperidol | Intravenous | Planned dose: 5 mg | Twice a day (bid) | Planned duration: 3 days | None |  |
|  | 3 | Ondansetron | Intravenous | Planned dose: 8 mg | Twice a day (bid) | Planned duration: 3 days | None |  |
| Boettger, 2011[20](#_ENREF_20) | 1 | Haloperidol | Not reported | Titrated dose: Mean 4.6mg (Range: 1 to 10mg) | Not reported | Not reported | None | Mean dose was 4.6 mg (range 1 to 10 mg) at baseline, 4.9 mg (range 1 to 10 mg) at T2 (days 2 to 3), and 4.8 mg (range 1 to 16 mg) at T3 (4 to 7 days) |
|  | 2 | Risperidone | Not reported | Titrated dose: Mean 1.0 (Range: 0.25 to 2) | Not reported | Not reported | None | Mean dose was 1.0 mg (0.25 to 2 mg) at baseline, 1.2 mg (range 0.25 to 3 mg) at T2 (days 2 to 3), and 1.3 mg (0.25 to 3 mg) at T3 (days 4 to 7). |
| Boettger, 2015[21](#_ENREF_21) | 1 | Aripiprazole | Not reported | Titrated dose: Mean 15.2mg (Range: 5 to 30mg) | Not reported | Not reported | None | Mean dose was 15.2 mg (range 5 to 30 mg) at baseline, 16.0 mg (range 10 to 30 mg) at T2 (2 to 3 days), and 18.3 mg (range 10 to 30 mg) at T3 (4 to 7 days). |
|  | 2 | Haloperidol | Not reported | Titrated dose: Mean 4.9mg (Range: 1.5 to 16mg) | Not reported | Not reported | None | Mean dose was 4.9 mg (range 1, 5 to 16mg) at baseline, 5.5 mg (range 1.5 to 16mg) at T2 (2 to 3 days), and 5.5 mg (range 1.5 to 16mg) at T3 (4 to 7 days). |
|  | 3 | Olanzapine | Not reported | Titrated dose: Mean 3.5mg (Range: 2.5 to 10mg) | Not reported | Not reported | None | Mean dose was 3.5 mg (range 2.5 to 10 mg) at baseline, 5.2 mg (range 2.5 to 15 mg) at T2 (2 to 3 days), and 7.1 mg (range 2.5 to 20 mg) at T3 (4 to 7 days). |
|  | 4 | Risperidone | Not reported | Titrated dose: Mean 0.9mg (Range: 0.5 to 2mg) | Not reported | Not reported | None | Mean dose was 0.9 mg (range 0.5 to 2 mg) at baseline, 1.1 mg (range 0.5 to 3 mg) at T2 (2 to 3 days), and 1.3 mg (range 0.5 to 3 mg) at T3 (4 to 7 days). |

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Breitbart, 1996[22](#_ENREF_22) | 1 | Chlorpromazine | Oral or intramuscular | Titrated dose: Oral: 10 to 200mg, Intramuscular: 5 to 100mg | Per day | Planned duration: 6 days | None | "The maintenance dose was equal to one to half of the first 24 hour dose requirement, given twice a day regimen." |
|  | 2 | Haloperidol | Oral or intramuscular | Titrated dose: oral: 0.25 to 5.0mg, Intramuscular: 0.125 to 3.0mg | Per day | Planned duration: 6 days | None | "The maintenance dose was equal to one to half of the first 24 hour dose requirement, given twice a day regimen." |
|  | 3 | Lorazepam | Oral or intramuscular | Titrated dose: Oral: 0.50 to 4.0mg, Intramuscular: 0.2 to 2.0mg | Per day | Planned duration: 6 days | None | "The maintenance dose was equal to one to half of the first 24 hour dose requirement, given twice a day regimen." |
| Breitbart, 2002[23](#_ENREF_23) | 1 | Olanzapine | Oral | Titrated dose: Mean 3.0mg (Range: 2.5 to 10mg) | either once or twice a day | Not reported | None | Mean dose was 3.0 mg (range 2.5 to 10mg) at baseline, 4.6 mg (range 2.5 to 15 mg) at T2 (days 2 to 3), and 6.3 mg (range 2.5 to 20mg) at T3 (days 4 to 7). |
| Carrasco, 2016[24](#_ENREF_24) | 1 | Haloperidol | Intravenous | Titrated dose: (Range: 0.5 to 1mg/hr) | Not reported | Not reported | None |  |
| Charoenporn, 2018[25](#_ENREF_25) | 1 | Haloperidol | Oral | Titrated dose: Mean 0.9mg; Median 0.5mg | Not reported | Planned duration: 7 days | None |  |
|  | 2 | Quetiapine | Oral | Titrated dose: Mean 26.7; Median 25 | Not reported | Planned duration: 7 days | None |  |
|  | 3 | Risperidone | Oral | Titrated dose: Mean 0.6mg; Median 0.5mg | Not reported | Planned duration: 7 days | None |  |

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Devlin, 2010[26](#_ENREF_26) | 1 | Placebo | either orally or via NG tube | Titrated dose: Mean 50; Median 210mg (IQR 116 to 293); Maximum 200mg | Twice a day (bid) | Median: 186 (IQR 108 to 228) hours; Planned dose: 10 days or earlier if shows no signs of delirium or if ICU discharge prior to 10 days of therapy | None |  |
|  | 2 | Quetiapine | Either orally or NG tube | Titrated dose: Mean 50; Median 110mg (IQR 88 to 191); Maximum 200mg | Twice a day (bid) | Median: 102 (IQR 84 to 168) hours; Planned dose: 10 days or earlier if shows no signs of delirium or If ICU discharge prior to 10 days of therapy | None |  |
| Drinkwater, 2014[27](#_ENREF_27) | 1 | Placebo | Intravenous | Planned dose: 5ml (0.9% saline)ml | 8 hourly | Planned duration: until patient delirium free for 48 hours (CAM to ICU)until discharged or after 14 days | None | For non to resolving agitation, open to label haloperidol could be administered in 2.5 to 5mg doses up to 10 mg in a 24 to hour period |
|  | 2 | Haloperidol | Intravenous | Planned dose: 2.5mg | 8 hourly | Planned duration: delirium free for 48 hours (CAM to ICU) or until 14 days or until discharged | None |  |
| Fox, 2018[28](#_ENREF_28) | 1 | Lurasidone | Not reported | Titrated dose: Mean 42.6mg | Not reported | Not reported | None | Overall duration of atypical antipsychotic treatment during the hospital stay was similar (6.0 [5.0 to 11.5] vs 11.0 [7.0 to 16.0] days, P = 0.28). |
|  | 2 | Quetiapine | Not reported | Titrated dose: Mean 153.8mg | Twice a day (bid) | Not reported | None | Overall duration of atypical antipsychotic treatment during the hospital stay was similar (6.0 [5.0 to 11.5] vs 11.0 [7.0 to 16.0] days, P = 0.28). |

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Girard, 2010[4](#_ENREF_4) | 1 | Placebo | Oral | Planned dose: 5ml | Twice a day (bid) | Median: 5 (IQR 3 to 7) days | None |  |
|  | 2 | Haloperidol | Oral | Planned dose: 5mg; Median: 15mg (10.8 to 17) | Per day | Median: 7 (4 to 10) | None | After enrollment 5 mg haloperidol as a solution, if no temporary gastric access IM (no more than 8 total doses). Second dose to 12 hour, then subsequent doses every 6 hours. Frequency reduced to every 8 hour when CAM to ICU negative on 2 consecutive assessments; reduced to every 12 hours when patients were delirium/coma to free on three consecutive assessments, and discontinued when patients were delirium/coma to free on four consecutive assessments. Frequency was reduced in a similar manner when patients were over sedated (RASS ≥2 levels deeper than target RASS). Dosing frequency was increased when over sedation resolved. All study drug was discontinued on study day 14. |
|  | 3 | Ziprasidone | Oral | Planned dose: 40mg; Median: 113mg (81 to 140) | Per day | Median: 4 (3 to 10) | None |  |
| Girard, 2018[29](#_ENREF_29) | 1 | Placebo | Intravenous | Titrated dose: Not reported | Twice a day (bid) | Median: 4; Planned dose: 14 days or until discharge | None | First dose for <70: 0.5ml placebo. First dose for ≥70: 0.25ml. Placebo administered every 12 hours |
|  | 2 | Haloperidol | Intravenous | Titrated dose: Mean 11; Median ; Maximum 10mg | Twice a day (bid) | Median: 4; Planned dose: 14 days or until discharge | None | First dose for <70: 2.5mg per 0.5ml haloperidol. First dose for ≥70: 1.25mg per 0.25ml haloperidol. Administered every 12 hours |
|  | 3 | Ziprasidone | Intravenous | Titrated dose: Mean 20; Median ; Maximum 20mg | Twice a day (bid) | Median: 4; Planned dose: 14 days or until discharge | None | First dose for <70: 5mg per 0.5ml ziprasidone. First dose for ≥70: 2.5mg per 0.25ml ziprasidone. Administered every 12 hours |

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Grover, 2011[30](#_ENREF_30) | 1 | Haloperidol | Oral | Titrated dose: Mean 0.88mg (Range: 0.25 to 5mg per day) | Per day | Planned duration: 6 days | Orientation and therapeutic activities, Vision and hearing, Psychoactive medication protocol |  |
|  | 2 | Olanzapine | Oral | Titrated dose: Mean 3.05mg (Range: 1.25 to 10 mg per day) | Per day | Planned duration: 6 days | Orientation and therapeutic activities, Vision and hearing, Psychoactive medication protocol |  |
|  | 3 | Risperidone | Oral | Titrated dose: Mean 0.95mg (Range: 0.5 to 2.0mg per day) | per day | Planned duration: 6 days | Orientation and therapeutic activities, Vision and hearing, Psychoactive medication protocol |  |
| Grover, 2016[31](#_ENREF_31) | 1 | Haloperidol | Oral | Titrated dose: Mean 0.67 ± 0.35mg (Range: 0.25 to 1.25mg) | per day | Planned duration: 6 days | Orientation and therapeutic activities, Vision and hearing, Psychoactive medication protocol |  |
|  | 2 | Quetiapine | Oral | Titrated dose: Mean 31.83 ±4.10mg (Range: 12.5 to 75mg) | Per day | Planned duration: 6 days | Orientation and therapeutic activities, Vision and hearing, Psychoactive medication protocol | Note that mean/SD for seroquel differs between text (results on page 368) and Table 1 26.63 +/`15.61, but the range is same |

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Han, 2004[32](#_ENREF_32) | 1 | Haloperidol | Oral | Titrated dose: Mean 1.7mg (Range: 1.0 to 3.0mg) | Twice a day (bid) | Planned duration: 7 days | None | At the end of the study (the seventh day), the mean dose of the haloperidol group was 1.71 mg (SD0.84, range1.0–3.0); The initial starting dose of each drug was 0.75 mg (haloperidol) or 0.5 mg (risperidone) twice a day. The dosage was increased depending on the status of delirium during the 7 days. |
|  | 2 | Risperidone | Oral | Titrated dose: Mean 1.02mg (Range: 0.5 to 2.0mg) | Twice a day (bid) | Planned duration: 7 days | None | The initial starting dose of each drug was 0.75 mg (haloperidol) or 0.5 mg (risperidone) twice a day. The dosage was increased depending on the status of delirium during the 7 days. At the end of the study (the seventh day), the mean dose of the haloperidol group was 1.71 mg (SD0.84, range1.0–3.0), and the mean dose of the risperidone group was 1.02 mg (SD0.41, range0.5–2.0). |
| Hatta, 2014[33](#_ENREF_33) | 1 | Aripiprazole | Not reported | Titrated dose: Maximum 7.23mg | Not reported | Not reported | None | 43% of patients took this drug for 1 week or less; 25% for 2 weeks or less, and 33% for over 2 weeks; There was a priority for non to pharmacological management for delirium, which included minimize drug side effects, fluid repletion, orientation and therapeutic activities, limit sensory underload or overload, and early mobilization. |
|  | 2 | Haloperidol | Intravenous | Titrated dose: Maximum 6.40mg | Not reported | Not reported | None | 52% of patients took this drug for 1 week or less; 19% for 2 weeks or less, and 29% for over 2 weeks; There was a priority for non to pharmacological management for delirium, which included minimize drug side effects, fluid repletion, orientation and therapeutic activities, limit sensory underload or overload, and early mobilization. |

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Hatta, 2014[33](#_ENREF_33) (continued) | 3 | Olanzapine | Not reported | Titrated dose: Maximum 10.2mg | Not reported | Not reported | None | 67% of patients took this drug for 1 week or less; 17% for 2 weeks or less, and 18% for over 2 weeks; There was a priority for non to pharmacological management for delirium, which included minimize drug side effects, fluid repletion, orientation and therapeutic activities, limit sensory underload or overload, and early mobilization. |
|  | 4 | Quetiapine | Not applicable | Titrated dose: Maximum 71.8mg | Not reported | Not reported | None | 60% of patients took this drug for 1 week or less; 19% for 2 weeks or less, and 21% for over 2 weeks; There was a priority for non to pharmacological management for delirium, which included minimize drug side effects, fluid repletion, orientation and therapeutic activities, limit sensory underload or overload, and early mobilization. |
|  | 5 | Risperidone | Not applicable | Titrated dose: Maximum 1.35mg | Not reported | Not reported | None | 49% of patients took this drug for 1 week or less; 25% for 2 weeks or less, and 26% for over 2 weeks; There was a priority for non to pharmacological management for delirium, which included minimize drug side effects, fluid repletion, orientation and therapeutic activities, limit sensory underload or overload, and early mobilization. |
| Horikawa, 2003[34](#_ENREF_34) | 1 | Risperidone | Oral | Titrated dose: 0.5mg | Once a day (qd) | Mean: 19.4 days | None | Haloperidol at a dose of 0.75 to 5.0 mg/day had been used in all patients, but not continuously, without any effect. |
| Hu, 2006[35](#_ENREF_35) | 1 | None | Not applicable | Not reported | Not reported | Planned duration: 1 week | None | Given somatic treatment aiming at delirium, not any drug for central nervous system was used |
|  | 2 | Haloperidol | Intramuscular | Titrated dose: (Range: 2.5 to 10mg) | Once a day (qd) | Planned duration: 1 week | None |  |
|  | 3 | Olanzapine | Oral or sublingually | Titrated dose: (Range: 1.25 to 20mg) | Once a day (qd) | Planned duration: 1 week | None |  |

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Hui, 2017[36](#_ENREF_36) | 1 | Haloperidol | Intravenous | Titrated dose: Not reported | 2 mg every 4 hours, and another 2 mg every hour as needed for agitation | Planned duration: Until discharge | None |  |
| Ikezawa, 2008[37](#_ENREF_37) | 1 | Risperidone | Oral | Titrated dose: Mean 1.5 (0.7) (Range: 0.5 to 3mg) | Once or twice | Mean: 11.7 (3.5) | None |  |
| Jain, 2017[38](#_ENREF_38) | 1 | Haloperidol | Oral | Titrated dose: Mean 2.10mg | Once a day (qd) | Mean: 3.37 days | None |  |
|  | 2 | Olanzapine | Oral | Titrated dose: Mean 5.49mg | Once a day (qd) | Mean: 3.57 days | None |  |
| Kim, 2001[39](#_ENREF_39) | 1 | Olanzapine | Oral | Titrated dose: Mean 5.9 (1.5); Median ; Maximum 8.8 (2.2) | Not reported | Mean: 6.6 (1.7) | None |  |
| Kim, 2003[40](#_ENREF_40) | 1 | Quetiapine | Not reported | Titrated dose: 25mg | Twice a day (bid) | Planned duration: 3 months | None | Mean dose is the mean dose when patients were maximally stabilized. |
| Kim, 2005[41](#_ENREF_41) | 1 | Haloperidol | Not reported | Titrated dose: Not reported | Not reported | Mean: 8.5 days | None | Mean starting dose: 2.67 mg (range 0.75 to 10.0 mg/day); Mean ending dose 1.67 mg (range 0.50 to 2.50 mg/day). |
|  | 2 | Risperidone | Not reported | Titrated dose: Not reported | Not reported | Mean: 4.8 days | None | Mean starting dose 0.97 mg (range 0.5 to 5.0 mg/day); mean ending dose 1.19 (range 0.5 to 5.0 mg/day) |
| Kim, 2010[42](#_ENREF_42) | 1 | Olanzapine | Not reported | Titrated dose: Mean 2.4± 1.7mg (Range: 1.25 to 7.5mg) | Per day | Planned duration: 7 days | None | The mean doses at last observation 2.4 ± 1.7 for olanzapine group |
|  | 2 | Risperidone | Not reported | Titrated dose: Mean 0.9 ± 0.6mg (Range: 0.25 to 2mg) | Per day | Planned duration: 7 days | None | The mean doses of last observation were 0.9 ± 0.6 mg/day |
| Kishi, 2012[43](#_ENREF_43) | 1 | Risperidone | Oral | Titrated dose: Mean 1.4mg | Once a day (qd) | Planned duration: 7 days | None |  |

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Konkayev, 2015[44](#_ENREF_44) | 1 | Dexmedetomidine | Infusion | Titrated dose: Median 0.93mg/kg/hour (Range: 0.2 to 1.4mg/kg/hour) | Continuous | Not reported | Pain management | Fentanyl and propofol were also used to manage symptoms, if necessary; Less people in the dexmedetomidine group (10%) were on propofol than in the haloperidol (42%). More people in the haloperidol group (72%) were on fentanyl than in the dexmedetomidine group (43%). |
|  | 2 | Haloperidol | Intravenous infusion | Titrated dose: Median 0.12mg/kg/h (Range: 0.10 to 0.15mg/kg/h) | Continuous | Not reported | Pain management |  |
| Lee, 2005[45](#_ENREF_45) | 1 | Quetiapine | Not reported | Titrated dose: Mean 113 ± 85.5mg (Range: 50 to 300mg) | Per day | Planned duration: or into remission | None |  |
|  | 2 | Amisulpride | Not reported | Titrated dose: Mean 156.4±97.5mg (Range: 50 to 800mg) | Per day | Planned duration: or remission | None |  |
| Lim, 2007[46](#_ENREF_46) | 1 | Haloperidol | Intramuscular | Titrated (5 to 20 mg) | Other: More than 2 hours apart | Not reported | None |  |
|  | 2 | Olanzapine | Intramuscular | Titrated (5 to 20 mg) | Other: More than 2 hours apart | Not reported | None |  |
| Lin, 2008[47](#_ENREF_47) | 1 | Haloperidol | Oral | Titrated dose: start dose 5mg | Once a day (qd) | Planned duration: 7 days | None |  |
|  | 2 | Olanzapine | Oral | Titrated dose: start dose 5mg | Once a day (qd) | Planned duration: 7 days | None |  |
| Maneeton, 2007[48](#_ENREF_48) | 1 | Quetiapine | Oral | Titrated dose: Mean 45.7 (28.7); Maximum 100mg (Range: 25 to 100mg) | Once or twice per day | Planned duration: 7 days | None | Dose between 25 to 100 mg/day; Mean start dose (SD) is 36.8 (24.8); During the present study, lorazepam at the maximum dose of 2 mg/day was an additional medication that could be used if needed but never used for any of patients Mean (SD) |
| Maneeton, 2013[49](#_ENREF_49) | 1 | Haloperidol | Oral | Titrated dose: Mean 0.8 (SD 0.3) (Range: 0.5 to 2.0mg) | Per day | Planned duration: 7 days | Orientation and therapeutic activities |  |
|  | 2 | Quetiapine | Oral | Titrated dose: Mean 67.6 (SD 9.7) (Range: 25 to 100mg) | per day | Planned duration: 7 days | Orientation and therapeutic activities |  |

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mittal, 2004[50](#_ENREF_50) | 1 | Risperidone | Not reported | Titrated dose: Mean 0.75mg | Twice a day (bid) | Planned duration: 5 days | None | Mean dosage on day 1 was 1.35 mg/day (range 1.0 to 2.0 mg/day). Mean maintenance dosage was 0.75 mg/day (range 0.5 to 1.50 mg/day). |
| Naksuk, 2017[51](#_ENREF_51) | 1 | None |  | Not reported |  | Not reported | None | This group developed delirium, but did not receive antipsychotics. |
|  | 2 | Haloperidol | Not reported | Titrated dose: Median 5.0mg (Range: 1.0 to 57.5mg) | Not reported | Median: 1.0 | None | Duration obtained from Table 2. Range in duration as 1 to 10 days; Dose is average dose per day, obtained from Table 2. |
|  | 3 | Quetiapine | Not reported | Titrated dose: Median 25.0mg (Range: 4.2 to 150.0mg) | Not reported | Median: 2.0 | None | Median duration obtained from Table 2. Range in duration was 1.0 to 8.0 days; Dose is average dose per day, obtained from Table 2. |
| Omura, 2003[52](#_ENREF_52) | 1 | Quetiapine | Not reported | Titrated dose: Mean 54.7mg (Range: 25 to 125mg) | once a day (13 patients), twice a day (5 patients), 3 times per day (6 patients) | Not reported | None |  |
| Pae, 2004[53](#_ENREF_53) | 1 | Quetiapine | Oral | Titrated dose: Mean 127.1mg | Not reported | Mean: 8.5 days | None |  |
| Page, 2013[10](#_ENREF_10) | 1 | Placebo | Intravenous | Planned dose: 0.5ml | Three times a day (tid) | Planned duration: 14 days or 2 consecutive days of delirium free coma free days or until discharge | Early mobilization, Pain management | Study drug was discontinued in all patients on ICU discharge, when the patient was delirium to free for two consecutive days, or after a maximum of 14 days treatment, whichever came first.; The same volumes administered IV: 0.5 ml of study drug (2.5 mg dissolved) and placebo |
|  | 2 | Haloperidol | Intravenous | Planned dose: 2.5mg | Three times a day (tid) | Planned duration: 14 days or 2 consecutive days of delirium free coma free days or until discharge | Early mobilization, Pain management | Study drug was discontinued in all patients on ICU discharge, when the patient was delirium to free for two consecutive days, or after a maximum of 14 days treatment, whichever came first; The same volumes administered IV: 0.5 ml of study drug (2.5 mg dissolved) and placebo |
| Parellada, 2004[54](#_ENREF_54) | 1 | Risperidone | Oral | Titrated dose: Mean day 1, 2.6; day 3, 2.6; day 7, 1.5mg | Twice a day (bid) | Planned duration: 7 days | None |  |

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sasaki, 2003[55](#_ENREF_55) | 1 | Quetiapine | Oral | Titrated dose: Mean 44.9; Median ; Maximum 63.5mg | Once a day (qd) | Mean: 4.8 days | None |  |
| Sipahimalani, 1998[56](#_ENREF_56) | 1 | Haloperidol | Orally, except one patient received haloperidol intravenously | Titrated dose: (Range: 1.5 to 10mg) | Not reported | Mean: 14.6 days | None |  |
|  | 2 | Olanzapine | Not reported | Titrated dose: Mean 8.2; Median ; Maximum 15mg | Once a day (qd) | Mean: 23.6 days | None |  |
| Skrobik, 2004[57](#_ENREF_57) | 1 | Haloperidol | Oral | Titrated dose: Mean 6.5mg (Range: 1 to 28mg) | per day | Not reported | None | Duration of therapy is not mentioned, but the study data is collected for 5 days, so can we assume the duration of therapy as 5 days. |
|  | 2 | Olanzapine | Oral | Titrated dose: Mean 4.54mg (Range: 2.5 to 13.5mg) | per day | Not reported | None |  |
| Straker, 2006[58](#_ENREF_58) | 1 | Aripiprazole | Not reported | Titrated dose: Mean 8.9mg (Range: 5 to 15mg) | Not reported | Planned duration: 7 days | None | Only two patients received a dose higher than 10 mg; Four patients also received as to needed haloperidol in the first few days of treatment. |
| Tahir, 2010[59](#_ENREF_59) | 1 | Placebo | Oral | Titrated dose: Mean 25; Maximum 175mg | Once a day (qd) | Planned duration: 10 days | None |  |
|  | 2 | Quetiapine | Oral | Titrated dose: Mean 40mg (Range: 25 to 175mg) | Once a day (qd) | Planned duration: 10 days | None |  |

| Author, year | Arm | Drug | Route of Administration | Dose | Frequency | Duration | Non-pharmaceutical intervention | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Toda, 2005[60](#_ENREF_60) | 1 | Risperidone | Oral | Titrated dose: Mean 0.92; Median ; Maximum 1.38 | Once a day (qd) | Planned duration: until remission, which ranged from 1 to 48 days | None |  |
| Yoon, 2011[61](#_ENREF_61) | 1 | Paliperidone | Oral | Titrated dose: Mean 3.75 (1.06); Maximum 9mg | Once a day (qd) | Planned duration: 7 days | None | Start dose was 3 mg/d |
| Yoon, 2013[62](#_ENREF_62) | 1 | Haloperidol | Not reported | Titrated dose: Mean 1.2mg (Range: 0.5 to 10mg) | Not reported | Mean duration: 4.7 days; Planned duration: 6 days | None | The initial starting dose was determined on the basis of age, degree of severity of delirium, and the general medical or postsurgical condition of the individual subject. Dose was adjusted according to clinical judgment based on daily overall impression of delirium over 6 days primarily, and on clinical assessments of the degree of improvement in delirium symptoms and the +/ to of adverse events. |
|  | 2 | Olanzapine | Not reported | Titrated dose: Mean 2.9mg (Range: 1 to 20mg) | Not reported | Mean duration: 5.3; Planned duration: 6 days | None |  |
|  | 3 | Quetiapine | Not reported | Titrated dose: Mean 47.9mg (Range: 25 to 200mg) | Not reported | Mean duration: 4.8 days; Planned duration: 6 days | None |  |
|  | 4 | Risperidone | Not reported | Titrated dose: Mean 1.1mg (Range: 0.25 to 4mg) | Not reported | Mean duration: 5.1 days; Planned duration: 6 days | None |  |

bid=twice daily; bid=twice daily; g=gram; IQR=interquartile range; mg/d=milligram per day; mg/hr=milligram per hour; mg=milligram; ml=millimeter; NG=nadogastric tube; qd=once daily; SD=standard deviation; T3=time point three; ug/kg=microgram per kilogram